We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Heptares Announces Agreement with Novartis Option Fund to Apply its StaR™ Technology

News   Oct 29, 2009

 
Heptares Announces Agreement with Novartis Option Fund to Apply its StaR™ Technology
 
 
Advertisement
 

RELATED ARTICLES

How Parkinson's Protein Destroys Cell Membranes

News

A newly developed method has revealed how the composition of cell membranes seems to be a decisive factor for how small quantities of α-synuclein cause damage.

READ MORE

Novel Pathology Could Improve Diagnosis and Treatment of Huntington’s Disease

News

Researchers have discovered a novel pathology that occurs in several human neurodegenerative diseases, including Huntington’s disease, and could be used to improve their diagnosis and treatment.

READ MORE

Next-generation Sequencing To Provide Precision Medicine for Rare Metabolic Disorders

News

Scientists have uncovered the genetic basis of aromatase deficiency – a rare metabolic disorder – using next-generation sequencing, paving the way towards precision medicine.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE